| Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B‐mediated drug–drug interactions using population pharmacokinetic modeling and simulation S Barnett, K Ogungbenro, K Ménochet, H Shen, Y Lai, WG Humphreys, ... Clinical Pharmacology & Therapeutics 104 (3), 564-574, 2018 | 65 | 2018 |
| In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems SL Beedie, HM Rore, S Barnett, CH Chau, W Luo, NH Greig, WD Figg, ... Oncotarget 7 (22), 33237, 2016 | 45 | 2016 |
| Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared with rosuvastatin and coproporphyrin I S Barnett, K Ogungbenro, K Menochet, H Shen, WG Humphreys, ... Journal of Pharmacology and Experimental Therapeutics 368 (1), 125-135, 2019 | 43 | 2019 |
| Anticancer properties of a novel class of tetrafluorinated thalidomide analogues SL Beedie, CJ Peer, S Pisle, ER Gardner, C Mahony, S Barnett, ... Molecular cancer therapeutics 14 (10), 2228-2237, 2015 | 29 | 2015 |
| Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients S Barnett, F Hellmann, E Parke, G Makin, DA Tweddle, C Osborne, ... European Journal of Cancer 164, 127-136, 2022 | 24 | 2022 |
| PBPK model of coproporphyrin I: evaluation of the impact of SLCO1B1 genotype, ethnicity, and sex on its inter‐individual variability H Takita, S Barnett, Y Zhang, K Ménochet, H Shen, K Ogungbenro, ... CPT: Pharmacometrics & Systems Pharmacology 10 (2), 137-147, 2021 | 24 | 2021 |
| Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance AL Nijstad, S Barnett, A Lalmohamed, IM Bérénos, E Parke, V Carruthers, ... European Journal of Cancer 164, 137-154, 2022 | 13 | 2022 |
| Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom S Barnett, J Kong, G Makin, GJ Veal British Journal of Clinical Pharmacology 87 (2), 256-262, 2021 | 9 | 2021 |
| Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population S Barnett, J Errington, J Sludden, D Jamieson, V Poinsignon, A Paci, ... Pharmaceuticals 14 (3), 272, 2021 | 8 | 2021 |
| A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children AL Nijstad, WY Chu, E de Vos-Kerkhof, CF Enters-Weijnen, ... Pharmaceutical Research 39 (10), 2487-2495, 2022 | 7 | 2022 |
| Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations S Barnett, V Holden, Q Campbell-Hewson, GJ Veal Frontiers in Oncology 11, 815040, 2022 | 6 | 2022 |
| Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series V Carruthers, S Barnett, R Rees, T Arif, O Slater, R Ramanujachar, ... Pediatric Blood & Cancer 69 (7), e29722, 2022 | 2 | 2022 |
| A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors. PF Gallagher, G Naylor, S Bashir, X Yan, D Burke, ER Plummer, ... Journal of Clinical Oncology 40 (16_suppl), 3103-3103, 2022 | 2 | 2022 |
| Generation of evidence-based carboplatin dosing guidelines for neonates and infants S Barnett, G Makin, DA Tweddle, C Osborne, GJ Veal British Journal of Cancer 129 (11), 1773-1779, 2023 | 1 | 2023 |
| Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk D Damoiseaux, F Amant, JH Beijnen, S Barnett, GJ Veal, ADR Huitema, ... CPT: pharmacometrics & systems pharmacology 12 (12), 1931-1944, 2023 | | 2023 |
| GENERATION OF EVIDENCE-BASED DOSING GUIDELINES FOR NEONATES AND INFANTS RECEIVING CARBOPLATIN AND VINCRISTINE S Barnett, G Makin, D Tweddle, C Osborne, G Veal PEDIATRIC BLOOD & CANCER 70, S119-S120, 2023 | | 2023 |
| Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report S Barnett, AC Nyein, M Galler, D Jamieson, M Davies, P Connor, GJ Veal Cancer Chemotherapy and Pharmacology 92 (4), 325-328, 2023 | | 2023 |
| Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma. C Geurten, J Errington, S Barnett, H Patel, S Noor, V Saraff, GJ Veal, ... Pediatric Blood and Cancer 70 (9), 2023 | | 2023 |
| Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients V Carruthers, S Barnett, R Rees, T Arif, O Slater, R Ramanujachar, ... | | 2022 |
| Application of Coproporphyrin I Pbpk Model to Evaluate the Impact of Slco1b1 Genotype, Ethnicity, and Sex on Its Oatp1b-mediated Interactions. H Takita, S Barnett, Y Zhang, K Menochet, H Shen, K Ogungbenro, ... Clinical Pharmacology & Therapeutics 109, S83-S83, 2021 | | 2021 |
